Current Status and Future Suggestions for Innovative Drug Research and Development in China.
- Author:
Shu-Xia LIU
1
;
Yan WANG
1
;
Shuang YANG
1
;
Ya-Qing WANG
1
;
Mei-Mei XU
2
,
3
Author Information
- Publication Type:Review
- Keywords: competitive analysis; drug development; innovative drugs
- MeSH: China; Drug Development/trends*; Drug Approval; Pharmaceutical Research
- From: Chinese Medical Sciences Journal 2024;39(4):288-296
- CountryChina
- Language:English
- Abstract: In recent years, with the policy reform of new drug review and approval, China has ushered in a surge of innovative drug development. Based on the Pharnexcloud database and the Pharmcube database, we analyzed the innovative drugs approved for marketing and entered clinical trials in China, sorted out the major research and development (R&D) institutions and enterprises, the distribution of innovative drug target types, and the primary therapeutic areas of the approved innovative drugs, and compared with the global innovative drug R&D landscape. Since 2020, China's innovative drug development has shown a rapid growth trend, with intense competition among biopharmaceutical companies, and the emergence of a number of leading biopharmaceutical enterprises. Popular targets for clinical-stage and approved drugs include protein tyrosine kinase, epidermal growth factor receptor, vascular endothelial growth factor receptor, and others. Oncological diseases are the most active domain for new drug R&D in China, followed by infectious diseases and neurological diseases. Suggestions for future development are proposed to increase policy support, enhance R&D innovation investment, optimize pipeline layout, strengthen international cooperation, and focus on innovative targets. This review provides a reference for pharmaceutical R&D enterprises, scientific researchers, and government administrators.
